Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma

Dec 30 2016

• By Jung Won Shin

2016

Related Content

Green Cross Halts US, Europe GreenGene F Trials To Focus On China

Oct 17 2016

Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Oct 05 2016

Hanmi Toughens Controls As Employees Arrested For Insider Trading

Dec 15 2016

Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer

May 24 2016

Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Apr 06 2016

Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval

Nov 21 2016

Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?

Nov 02 2016

Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

Sep 30 2016

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Oct 07 2016

Korea To Limit Olmutinib Usage, Monitor All Patients

Oct 05 2016

Related Companies

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Pfizer Inc.

Genentech, Inc.

Biogen, Inc.

Teva Pharmaceutical Industries Ltd.

Samsung Bioepis Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Boehringer Ingelheim GmbH

Yuhan Corporation

GC Biopharma Corp.

CG Invites Co., Ltd.

Genentech, Inc.

Kolon Life Science, Inc.

Mitsubishi Tanabe Pharma Corporation

Additional Topics

South Korea Asia Pacific Commercial Deals Companies BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window